These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 29757355)
1. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355 [TBL] [Abstract][Full Text] [Related]
2. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors. Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223 [TBL] [Abstract][Full Text] [Related]
4. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. Taxonera C; Ponferrada Á; Riestra S; Bermejo F; Saro C; Martín-Arranz MD; Cabriada JL; Barreiro-de Acosta M; de Castro ML; López-Serrano P; Barrio J; Suarez C; Iglesias E; Argüelles-Arias F; Ferrer I; Marín-Jiménez I; Hernández-Camba A; Bastida G; Van Domselaar M; Martínez-Montiel P; Olivares D; Rivero M; Fernandez-Salazar L; Nantes Ó; Merino O; Alba C; Gisbert JP; J Crohns Colitis; 2018 Nov; 12(11):1270-1279. PubMed ID: 30052856 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents. Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815 [TBL] [Abstract][Full Text] [Related]
6. Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil. Amorim RF; Viegas ERC; Carneiro AJV; Esberard BC; Chinem ES; Correa RS; Rodrigues L; Ribeiro-Alves M; Silva KS; de Souza HS; Carvalho ATP Dig Dis Sci; 2019 Jul; 64(7):1916-1922. PubMed ID: 30673986 [TBL] [Abstract][Full Text] [Related]
7. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. Wang PH; Lin CH; Chang TH; Wu CS BMC Pulm Med; 2020 Aug; 20(1):232. PubMed ID: 32867745 [TBL] [Abstract][Full Text] [Related]
8. Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study. Tang I; So H; Luk L; Wong V; Pang S; Lao V; Yip R Hong Kong Med J; 2020 Apr; 26(2):111-119. PubMed ID: 32245912 [TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Nisar MK; Rafiq A; Östör AJ Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501 [TBL] [Abstract][Full Text] [Related]
10. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286 [TBL] [Abstract][Full Text] [Related]
11. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207 [TBL] [Abstract][Full Text] [Related]
12. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. Lee EH; Kang YA; Leem AY; Park MS; Kim YS; Kim SK; Chang J; Kim SY Sci Rep; 2017 Jul; 7(1):6473. PubMed ID: 28743918 [TBL] [Abstract][Full Text] [Related]
13. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000 [TBL] [Abstract][Full Text] [Related]
14. A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. Al-Taweel T; Strohl M; Pai M; Martel M; Bessissow T; Bitton A; Seidman E; Afif W Dig Dis Sci; 2018 Oct; 63(10):2695-2702. PubMed ID: 29968143 [TBL] [Abstract][Full Text] [Related]
16. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Cui X; Gao L; Cao B Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201 [TBL] [Abstract][Full Text] [Related]
17. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354 [TBL] [Abstract][Full Text] [Related]
18. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results. Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550 [TBL] [Abstract][Full Text] [Related]
19. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652 [TBL] [Abstract][Full Text] [Related]
20. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy. Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]